1-14 of 14
David Tucker
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Results of a Second, Prespecified Analysis of the Phase 2 Study ELM-2 Confirm High Rates of Durable Complete Response with Odronextamab in Patients with Relapsed/Refractory (R/R) Follicular Lymphoma (FL) with Extended Follow-up

Jose. C. Villasboas, Tae Min Kim, Michal Taszner, Silvana Novelli, Seok-Goo Cho, Michele Merli, Ana Jimenez Ubieto, Benoit Tessoulin, Michelle Poon, Jan Walewski, Shuhua Yi, Yuqin Song, Geoffrey Chong, Stefano Luminari, Emmanuel Bachy, Stephanie Guidez, Aranzazu Alonso, Deepa Jagadeesh, Wei Zhang, Laura Magnano, Elżbieta Iskierka-Jażdżewska, Monica Tani, Jessica Cai, Amulya Uppala, Saleem Shariff, Lei Chi, Aafia Chaudhry, Hesham Mohamed, Srikanth Ambati, David Tucker
Journal: Blood
Blood (2023) 142 (Supplement 1): 3041.
https://doi.org/10.1182/blood-2023-181650
Published: 2023
Journal Articles

Maintenance of Moderate to High Levels of Functioning and Quality of Life with Odronextamab Monotherapy in Patients with Relapsed or Refractory Follicular Lymphoma

Benoit Tessoulin, Seok-Goo Cho, Michal Taszner, Tae Min Kim, Silvana Novelli, Jose C. Villasboas, Michele Merli, Ana Jimenez Ubieto, Michelle Poon, David Tucker, Jan Walewski, Shuhua Yi, Yuqin Song, Geoffrey Chong, Emmanuel Bachy, Stephanie Guidez, Aranzazu Alonso, Deepa Jagadeesh, Wei Zhang, Laura Magnano, Elzbieta Iskierka-Jazdzewska, Monica Tani, Jessica Cai, Cristina Ivanescu, Matthew Reaney, Aafia Chaudhry, Hesham Mohamed, Srikanth Ambati, James Harnett, Lei Chi, Stefano Luminari
Journal: Blood
Blood (2023) 142 (Supplement 1): 669.
https://doi.org/10.1182/blood-2023-181942
Published: 2023
Journal Articles

Time Limited Exposure to a ROR1 Targeting Bispecific T Cell Engager (NVG-111) Leads to Durable Responses in Subjects with Relapsed Refractory Chronic Lymphocytic Leukemia (CLL) and Mantle Cell Lymphoma (MCL)

William Townsend, Sarah Leong, Mittal Shah, Toby Batten, David Tucker, Bryson Pottinger, Shankaranarayana Paneesha, Dima El-Sharkawi, Toby A. Eyre, Ho Pui Jeff Lam, Jiexin Zheng, Sarah Cook, David Granger, David Ahern, Kieran O'Donovan, Amit C. Nathwani, Parag Jasani
Journal: Blood
Blood (2023) 142 (Supplement 1): 329.
https://doi.org/10.1182/blood-2023-188607
Published: 2023
Journal Articles

Circulating Tumor DNA Analysis Associates with Progression-Free Survival (PFS) with Odronextamab Monotherapy in Relapsed/Refractory (R/R) Follicular Lymphoma (FL) and Diffuse Large B-Cell Lymphoma (DLBCL): Identification of Minimal Residual Disease Status and High-Risk Subgroups from the Phase 2 ELM-2 Study

Jon E. Arnason, Jurriaan Brouwer-Visser, Stefano Luminari, David Tucker, Tae Min Kim, Won Seog Kim, Laura Magnano, Dylan Sun, Jessica Cai, Kamil Cygan, Srikanth Ambati, Hesham Mohamed, Aafia Chaudhry, Vladimir Jankovic
Journal: Blood
Blood (2023) 142 (Supplement 1): 427.
https://doi.org/10.1182/blood-2023-179812
Published: 2023
Journal Articles

Odronextamab in Patients with Relapsed/Refractory (R/R) Follicular Lymphoma (FL) Grade 1-3a: Results from a Prespecified Analysis of the Pivotal Phase II Study ELM-2

Tae Min Kim, Michal Taszner, Seok-Goo Cho, Silvana Novelli, Steven Le Gouill, Michelle Limei Poon, Jose C. Villasboas, Rebecca Champion, Emmanuel Bachy, Stéphanie Guidez, Aránzazu Alonso Alonso, Deepa Jagadeesh, Michele Merli, David Tucker, Jingxian Cai, Carolina Leite De Oliveira, Min Zhu, Aafia Chaudhry, Hesham Mohamed, Srikanth R. Ambati, Stefano Luminari
Journal: Blood
Blood (2022) 140 (Supplement 1): 2280–2282.
https://doi.org/10.1182/blood-2022-158404
Published: 2022
Journal Articles

First-in-Human Phase I Trial of a ROR1 Targeting Bispecific T Cell Engager (NVG-111) in Combination with Ibrutinib or As Monotherapy in Subjects with Relapsed Refractory Chronic Lymphocytic Leukaemia (CLL) and Mantle Cell Lymphoma (MCL)

William Townsend, Sarah Leong, David Tucker, Bryson Pottinger, Shankara Paneesha, Dima El-Sharkawi, Toby A. Eyre, Toby Batten, Mittal Shah, Sarah Cook, David Granger, Kieran O'Donovan, Amit C. Nathwani, Parag Jasani
Journal: Blood
Blood (2022) 140 (Supplement 1): 4162–4163.
https://doi.org/10.1182/blood-2022-169658
Published: 2022
Journal Articles

The Use of Avapritinib in Advanced Systemic Mastocytosis: Report of an Open-Label Compassionate Use Program in the United Kingdom

Christopher J. Saunders, Chandan Saha, Priya Sriskandarajah, Helen Cashman, Andrew J Wilson, Jonathan Lambert, Matthew Lawes, David Tucker, Simone Green, Manish Jain, Victoria Stables, Juanah Addada, Theingi Yin, Huw Roddie, Bethan Psaila, Deepti H. Radia
Journal: Blood
Blood (2022) 140 (Supplement 1): 3976–3977.
https://doi.org/10.1182/blood-2022-166073
Published: 2022
Journal Articles

Ibrutinib improves survival compared with chemotherapy in mantle cell lymphoma with central nervous system relapse

Clinical Trials & Observations
Chiara Rusconi, Chan Y. Cheah, Toby A. Eyre, David Tucker, Pavel Klener, Eva Giné, Lara Crucitti, Cristina Muzi, Sara Iadecola, Gabriele Infante, Sophie Bernard, Rebecca L. Auer, Chiara Pagani, Monika Duglosz-Danecka, Heidi Mocikova, Tom van Meerten, Emanuele Cencini, Ana Marin-Niebla, Michael E. Williams, Piera Angelillo, Paolo Nicoli, Annalisa Arcari, Lucia Morello, Donato Mannina, Orsola Vitagliano, Roberto Sartori, Annalisa Chiappella, Roberta Sciarra, Piero M. Stefani, Martin Dreyling, John F. Seymour, Carlo Visco
Journal: Blood
Blood (2022) 140 (17): 1907–1916.
https://doi.org/10.1182/blood.2022015560
Published: 2022
Includes: Supplemental data
Journal Articles

Factors Influencing Time from Initial Presentation to Start of Plasma Exchange (PEX) in Patients with Acute Thrombotic Thrombocytopenic Purpura (TTP)

Rory McCulloch, FRCPath, MRCP, MBBS, Tom Bull, MBBS,FRCPath,MRCP, Phillip LR Nicolson, MA, MBBChir, MRCP, Rebecca J Shaw, MRCP, Zara Sayar, MD FRCPath, MRCP, Alexander Langridge, Michala Pettitt, PhD, Rita Perry, David Tucker, MD, Marie Scully, MD, HaemSTAR Collaborators. (# joint first authors)
Journal: Blood
Blood (2020) 136 (Supplement 1): 9–10.
https://doi.org/10.1182/blood-2020-133371
Published: 2020
Journal Articles

R-BAC Maintains High Response Rate in Mantle Cell Lymphoma Following Relapse on BTK Inhibitor Therapy

Rory McCulloch, FRCPath, MRCP, MBBS, Carlo Visco, Rebecca Frewin, Neil Phillips, Toby A. Eyre, David Tucker, MD, Francesca M. Quaglia, Annabel McMillan, Jonathan Lambert, Nicola Crosbie, Simon Rule
Journal: Blood
Blood (2019) 134 (Supplement_1): 3989.
https://doi.org/10.1182/blood-2019-129829
Published: 2019
Journal Articles

Ibrutinib at First Relapse for Mantle Cell Lymphoma: A United Kingdom Real World Analysis of Outcomes in 169 Patients

Rory McCulloch, FRCPath, MRCP, MBBS, Simon Rule, Toby A. Eyre, Harshita Goradia, Simon Bolam, MD, Thomas Creasey, MBBS, David Tucker, MD, Michelle Furtado, Oliver Miles, Samuel Harrison, Amir Shenouda, Andrew Robinson, Matthew Wilson, MD BSc, MRCP, Annabel McMillan, Nimish Shah, Graham McIlroy, MD, David Dutton, MD, Adam Bond, Luke Attwell, Alexander Langridge, Helen Parry, MB ChB, MRCP, PhD, John Willan, Gavin Campbell, FRCP,FRCPath, Deborah Turner, David Lewis, PhD FRCPath, BSc, Helen McCarthy, MBBS, PhD, Jonathan Lambert, Pamela McKay, MD, Neil Phillips, Shankara Paneesha, MD, Wendy Osborne, MD, Mark Bishton, Nicola Crosbie
Journal: Blood
Blood (2019) 134 (Supplement_1): 3993.
https://doi.org/10.1182/blood-2019-125947
Published: 2019
Journal Articles

A Retrospective Real-World Study of the Current Treatment Pathways for Myelofibrosis in the UK (The REALISM UK Study)

Adam J. Mead, MD PhD, Tim Somervaille, Professor, MD, Nauman M Butt, MD, Waseem Nagi, MD FRCPath, Alastair J Whiteway, MBBS, Suriya Kirkpatrick, MD, Ciro R Rinaldi, MD PhD, Catherine Roughley, MD, Sam Ackroyd, MD, Joanne Ewing, PhDBMBS BSc FRPATH, Pratap Neelakantan, MD FRCPath, Mamta Garg, MD FRCP, FRCPath, Claire N Harrison, Professor, David Tucker, MD, Rozinder Bains, Gavin Chiu, MBBS, MRCGP, MFPM, DPM, BSc, Joe Hickey, PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 1671.
https://doi.org/10.1182/blood-2019-124686
Published: 2019
Journal Articles

A Phase I/II, First in Human Trial of the Bruton's Tyrosine Kinase Inhibitor M7583 in Patients with B-Cell Malignancies

Wojciech Jurczak, Simon Rule, MD, William Townsend, MD FRCPath, David Tucker, Barbara Sarholz, Jürgen Scheele, John G. Gribben, Pier Luigi Zinzani, MD
Journal: Blood
Blood (2018) 132 (Supplement 1): 4161.
https://doi.org/10.1182/blood-2018-99-112808
Published: 2018
Journal Articles

First in Human, Phase I/II Trial of the Bruton's Tyrosine Kinase Inhibitor (BTKi) M7583 in Patients with B Cell Malignancies: Study Design and Initial Outcomes

Wojciech Jurczak, Simon Rule, MD, William Townsend, David Tucker, Martin Dyroff, Barbara Sarholz, Jürgen Scheele, John G. Gribben, MDDSc FMedSci, Pier Luigi Zinzani, MD
Journal: Blood
Blood (2017) 130 (Supplement 1): 2778.
https://doi.org/10.1182/blood.V130.Suppl_1.2778.2778
Published: 2017